AKT1 and non-small cell lung carcinoma: Consistent with our results, a recent phase II trial of erlotinib (anti-EGFR) plus MK-2206 (anti-Akt), conducted in patients with advanced NSCLC that previously progressed on erlotinib, provided proof of feasibility for Akt pathway inhibition to overcome acquired resistance to anti-EGFR agents29.